ES2370339T3 - Método normalizado y optimizado de reacción en cadena de la polimerasa de transcriptasa inversa cuantitativa en tiempo real para la detección de mrd en leucemia. - Google Patents

Método normalizado y optimizado de reacción en cadena de la polimerasa de transcriptasa inversa cuantitativa en tiempo real para la detección de mrd en leucemia. Download PDF

Info

Publication number: ES2370339T3
Authority: ES; Spain
Prior art keywords: samples; abl; transcript; pcr; gene
Prior art date: 2003-03-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES04718310T

Other languages

English (en)

Spanish (es)

Inventor

Jean Gabert

Emmanuel Beillard

Wanli Bi

Jacques Van Dongen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aix Marseille Universite

Original Assignee

Universite de la Mediterranee Aix Marseille II

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-07

Filing date

2004-03-08

Publication date

2011-12-14

2004-03-08 Application filed by Universite de la Mediterranee Aix Marseille II filed Critical Universite de la Mediterranee Aix Marseille II

2011-12-14 Application granted granted Critical

2011-12-14 Publication of ES2370339T3 publication Critical patent/ES2370339T3/es

2024-03-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 80
238000001514 detection method Methods 0.000 title claims abstract description 54
238000006243 chemical reaction Methods 0.000 title claims description 22
208000032839 leukemia Diseases 0.000 title description 34
108090000623 proteins and genes Proteins 0.000 claims abstract description 143
230000004927 fusion Effects 0.000 claims abstract description 59
208000007660 Residual Neoplasm Diseases 0.000 claims abstract description 55
108091008121 PML-RARA Proteins 0.000 claims abstract description 53
239000000523 sample Substances 0.000 claims description 197
238000004458 analytical method Methods 0.000 claims description 44
239000013610 patient sample Substances 0.000 claims description 43
239000013614 RNA sample Substances 0.000 claims description 39
239000002299 complementary DNA Substances 0.000 claims description 38
230000002441 reversible effect Effects 0.000 claims description 35
102100034343 Integrase Human genes 0.000 claims description 30
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 30
102100026008 Breakpoint cluster region protein Human genes 0.000 claims description 15
101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims description 15
239000002773 nucleotide Substances 0.000 claims description 14
125000003729 nucleotide group Chemical group 0.000 claims description 14
241000713869 Moloney murine leukemia virus Species 0.000 claims description 8
239000003153 chemical reaction reagent Substances 0.000 claims description 6
238000007405 data analysis Methods 0.000 claims description 4
101100532034 Drosophila melanogaster RTase gene Proteins 0.000 claims description 3
239000000872 buffer Substances 0.000 claims description 3
102000039446 nucleic acids Human genes 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims description 3
239000003161 ribonuclease inhibitor Substances 0.000 claims description 3
-1 ABL nucleic acids Chemical class 0.000 claims description 2
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 claims description 2
108020004711 Nucleic Acid Probes Proteins 0.000 abstract 1
239000002853 nucleic acid probe Substances 0.000 abstract 1
239000013615 primer Substances 0.000 description 200
230000014509 gene expression Effects 0.000 description 146
210000004027 cell Anatomy 0.000 description 142
108091032973 (ribonucleotides)n+m Proteins 0.000 description 114
238000010790 dilution Methods 0.000 description 108
239000012895 dilution Substances 0.000 description 108
210000005259 peripheral blood Anatomy 0.000 description 101
239000011886 peripheral blood Substances 0.000 description 100
108010081355 beta 2-Microglobulin Proteins 0.000 description 91
210000001185 bone marrow Anatomy 0.000 description 90
102000015736 beta 2-Microglobulin Human genes 0.000 description 89
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 71
238000003745 diagnosis Methods 0.000 description 61
239000013612 plasmid Substances 0.000 description 60
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 59
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 58
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 58
230000003321 amplification Effects 0.000 description 57
238000003199 nucleic acid amplification method Methods 0.000 description 57
108020004414 DNA Proteins 0.000 description 56
238000003752 polymerase chain reaction Methods 0.000 description 51
230000035945 sensitivity Effects 0.000 description 49
239000002987 primer (paints) Substances 0.000 description 48
241000282414 Homo sapiens Species 0.000 description 47
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 41
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 40
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 40
108700019889 TEL-AML1 fusion Proteins 0.000 description 36
208000031261 Acute myeloid leukaemia Diseases 0.000 description 35
238000012360 testing method Methods 0.000 description 35
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 34
238000012340 reverse transcriptase PCR Methods 0.000 description 30
101150033421 ABL gene Proteins 0.000 description 29
230000000875 corresponding effect Effects 0.000 description 24
238000002474 experimental method Methods 0.000 description 23
239000000463 material Substances 0.000 description 21
238000011002 quantification Methods 0.000 description 21
238000003556 assay Methods 0.000 description 19
238000012544 monitoring process Methods 0.000 description 18
101150076800 B2M gene Proteins 0.000 description 17
210000000349 chromosome Anatomy 0.000 description 17
102100026375 Protein PML Human genes 0.000 description 16
238000010586 diagram Methods 0.000 description 16
101150054900 gus gene Proteins 0.000 description 16
238000005457 optimization Methods 0.000 description 16
238000003908 quality control method Methods 0.000 description 16
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 15
101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 15
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 15
102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 14
238000013461 design Methods 0.000 description 13
238000010606 normalization Methods 0.000 description 12
238000011282 treatment Methods 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 11
101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 description 10
238000000429 assembly Methods 0.000 description 10
230000000712 assembly Effects 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
210000003719 b-lymphocyte Anatomy 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 8
101000610107 Homo sapiens Pre-B-cell leukemia transcription factor 1 Proteins 0.000 description 8
102000057361 Pseudogenes Human genes 0.000 description 8
108091008109 Pseudogenes Proteins 0.000 description 8
101710156592 Putative TATA-binding protein pB263R Proteins 0.000 description 8
102100040296 TATA-box-binding protein Human genes 0.000 description 8
101710145783 TATA-box-binding protein Proteins 0.000 description 8
102100038313 Transcription factor E2-alpha Human genes 0.000 description 8
238000013459 approach Methods 0.000 description 8
230000008901 benefit Effects 0.000 description 8
238000011156 evaluation Methods 0.000 description 8
239000002243 precursor Substances 0.000 description 8
101000798940 Gallus gallus Target of Myb protein 1 Proteins 0.000 description 7
101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 7
101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 description 7
102100036639 Myosin-11 Human genes 0.000 description 7
102100034391 Porphobilinogen deaminase Human genes 0.000 description 7
208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
102100023606 Retinoic acid receptor alpha Human genes 0.000 description 7
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 7
230000002860 competitive effect Effects 0.000 description 7
230000007774 longterm Effects 0.000 description 7
238000013207 serial dilution Methods 0.000 description 7
230000005945 translocation Effects 0.000 description 7
101150049556 Bcr gene Proteins 0.000 description 6
102000008147 Core Binding Factor beta Subunit Human genes 0.000 description 6
108010060313 Core Binding Factor beta Subunit Proteins 0.000 description 6
108700024394 Exon Proteins 0.000 description 6
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 6
102100040171 Pre-B-cell leukemia transcription factor 1 Human genes 0.000 description 6
208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 6
102100024952 Protein CBFA2T1 Human genes 0.000 description 6
238000001793 Wilcoxon signed-rank test Methods 0.000 description 6
230000000735 allogeneic effect Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000013642 negative control Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 5
230000027455 binding Effects 0.000 description 5
238000004364 calculation method Methods 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
230000002153 concerted effect Effects 0.000 description 5
238000011109 contamination Methods 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000012470 diluted sample Substances 0.000 description 5
238000003753 real-time PCR Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
229930002330 retinoic acid Natural products 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
229910001868 water Inorganic materials 0.000 description 5
102100025373 Runt-related transcription factor 1 Human genes 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
238000010804 cDNA synthesis Methods 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
238000009093 first-line therapy Methods 0.000 description 4
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000005087 mononuclear cell Anatomy 0.000 description 4
230000008520 organization Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
101150115276 tal1 gene Proteins 0.000 description 4
238000010200 validation analysis Methods 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
108020004463 18S ribosomal RNA Proteins 0.000 description 3
108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 3
102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 3
208000031404 Chromosome Aberrations Diseases 0.000 description 3
108700031469 E2A-Pbx1 fusion Proteins 0.000 description 3
102000053187 Glucuronidase Human genes 0.000 description 3
108010060309 Glucuronidase Proteins 0.000 description 3
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 3
102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 3
238000010240 RT-PCR analysis Methods 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
208000036676 acute undifferentiated leukemia Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000002509 fluorescent in situ hybridization Methods 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
238000010837 poor prognosis Methods 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000004393 prognosis Methods 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
101150023847 tbp gene Proteins 0.000 description 3
101150084750 1 gene Proteins 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
230000004568 DNA-binding Effects 0.000 description 2
108010048671 Homeodomain Proteins Proteins 0.000 description 2
102000009331 Homeodomain Proteins Human genes 0.000 description 2
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 2
101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 2
108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 2
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
102100025169 Max-binding protein MNT Human genes 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
101150016155 Pml gene Proteins 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
238000011529 RT qPCR Methods 0.000 description 2
101150066717 Rara gene Proteins 0.000 description 2
101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
108700009124 Transcription Initiation Site Proteins 0.000 description 2
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
210000001766 X chromosome Anatomy 0.000 description 2
230000004075 alteration Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
231100000005 chromosome aberration Toxicity 0.000 description 2
238000007596 consolidation process Methods 0.000 description 2
238000009108 consolidation therapy Methods 0.000 description 2
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
230000002559 cytogenic effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000002074 deregulated effect Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003147 molecular marker Substances 0.000 description 2
238000007857 nested PCR Methods 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000013517 stratification Methods 0.000 description 2
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
108091006106 transcriptional activators Proteins 0.000 description 2
108091006107 transcriptional repressors Proteins 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
108020004465 16S ribosomal RNA Proteins 0.000 description 1
COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
101150047313 52 gene Proteins 0.000 description 1
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010008805 Chromosomal abnormalities Diseases 0.000 description 1
102000006990 Core Binding Factors Human genes 0.000 description 1
108010072732 Core Binding Factors Proteins 0.000 description 1
102000001493 Cyclophilins Human genes 0.000 description 1
108010068682 Cyclophilins Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010007508 Farnesyltranstransferase Proteins 0.000 description 1
102000007317 Farnesyltranstransferase Human genes 0.000 description 1
208000034951 Genetic Translocation Diseases 0.000 description 1
101150001754 Gusb gene Proteins 0.000 description 1
101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 1
101150054386 Myh11 gene Proteins 0.000 description 1
108010084498 Myosin Heavy Chains Proteins 0.000 description 1
102000005604 Myosin Heavy Chains Human genes 0.000 description 1
101100083123 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pgk-1 gene Proteins 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102100022935 Nuclear receptor corepressor 1 Human genes 0.000 description 1
101710153661 Nuclear receptor corepressor 1 Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
101710120873 Porphobilinogen deaminase 2 Proteins 0.000 description 1
108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
238000013381 RNA quantification Methods 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
101150063267 STAT5B gene Proteins 0.000 description 1
101000980867 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Curved DNA-binding protein Proteins 0.000 description 1
101000982319 Shallot virus X Uncharacterized ORF4 protein Proteins 0.000 description 1
102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 1
108010062276 T-Cell Acute Lymphocytic Leukemia Protein 1 Proteins 0.000 description 1
102000011768 T-Cell Acute Lymphocytic Leukemia Protein 1 Human genes 0.000 description 1
201000011638 T-cell childhood acute lymphocytic leukemia Diseases 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000006290 Transcription Factor TFIID Human genes 0.000 description 1
108010083268 Transcription Factor TFIID Proteins 0.000 description 1
102100039580 Transcription factor ETV6 Human genes 0.000 description 1
102000007238 Transferrin Receptors Human genes 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 description 1
108700025690 abl Genes Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
101150105847 actba gene Proteins 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
201000011186 acute T cell leukemia Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 1
238000011366 aggressive therapy Methods 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000013394 immunophenotyping Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
229940042040 innovative drug Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000003771 laboratory diagnosis Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000002122 leukaemogenic effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
230000005868 ontogenesis Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
238000011155 quantitative monitoring Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
230000011218 segmentation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012549 training Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Oncology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

ES04718310T 2003-03-07 2004-03-08 Método normalizado y optimizado de reacción en cadena de la polimerasa de transcriptasa inversa cuantitativa en tiempo real para la detección de mrd en leucemia. Expired - Lifetime ES2370339T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03290572A EP1454994A1 (de)	2003-03-07	2003-03-07	Standardisiertes und optimiertes quantitatives Reverse-Transkriptase-Echtzeit-Polymerasekettenreaktionsverfahren zum Nachweis von minimalen Resterkrankungen bei Leukämie
EP03290572		2003-03-07

Publications (1)

Publication Number	Publication Date
ES2370339T3 true ES2370339T3 (es)	2011-12-14

Family

ID=32799106

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES04718310T Expired - Lifetime ES2370339T3 (es)	2003-03-07	2004-03-08	Método normalizado y optimizado de reacción en cadena de la polimerasa de transcriptasa inversa cuantitativa en tiempo real para la detección de mrd en leucemia.
ES07007462T Expired - Lifetime ES2337301T3 (es)	2003-03-07	2004-03-08	Metodo normalizado y optimizado de reaccion en cadena de la polimerasa de transcriptasa inversa en tiempo real para la deteccion de mrd en leucemia.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES07007462T Expired - Lifetime ES2337301T3 (es)	2003-03-07	2004-03-08	Metodo normalizado y optimizado de reaccion en cadena de la polimerasa de transcriptasa inversa en tiempo real para la deteccion de mrd en leucemia.

Country Status (7)

Country	Link
US (2)	US20060240434A1 (de)
EP (5)	EP1454994A1 (de)
JP (1)	JP4706863B2 (de)
AT (2)	ATE518004T1 (de)
DE (1)	DE602004023659D1 (de)
ES (2)	ES2370339T3 (de)
WO (1)	WO2004078020A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8206920B2 (en) *	2007-03-26	2012-06-26	Arnold Ganser	Diagnostic assay for the specific treatment of acute myeloid leukemia
CN101624621B (zh) *	2008-07-11	2012-01-18	北京大学人民医院	一种定量检测BCR/ABL mRNA水平的试剂盒
US9777332B2 (en)	2011-03-31	2017-10-03	St. Jude Children's Research Hospital	Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2013119950A2 (en) *	2012-02-08	2013-08-15	Insight Genetics, Inc.	Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
MA35216B1 (fr) *	2012-09-13	2014-07-03	Mascir	Sondes et amorces pour la detection du gene bcr-abl en reaction duplex
CN102925556B (zh) *	2012-09-29	2014-09-17	童永清	一种检测m BCR融合基因mRNA表达量的试剂盒
CN102876799B (zh) *	2012-10-18	2014-01-01	北京大学人民医院	用于检测mll相关融合基因的多重实时定量pcr试剂盒
MA36330B1 (fr) *	2013-10-10	2016-04-29	Mascir Morrocan Foundation For Advanced Science Innovation & Res	Kit de diagnostic de la leucemie myeloide chronique en reaction multiplex et ses applications dans le suivi du traitement et de la maladie residuelle
EP3201358A1 (de) *	2014-10-02	2017-08-09	Université de Montréal	Marker für schlechte prognose von akuter myeloischer leukämie und verwendungen davon
JP6531312B2 (ja) *	2014-10-17	2019-06-19	東洋鋼鈑株式会社	Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法
WO2016183679A1 (en) *	2015-05-21	2016-11-24	Université de Montréal	Prognostic markers of acute myeloid leukemia survival
CN106399462A (zh) *	2015-07-27	2017-02-15	上海睿玻生物科技有限公司	一种bcr-abl融合基因扩增试剂盒和检测试剂盒
RU2638800C2 (ru) *	2015-12-29	2017-12-15	Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН)	Способ определения маркеров наличия опухолевых в-лимфобластов
CN107674914A (zh) *	2016-08-02	2018-02-09	熊术道	一步单管法定量rt‑pcr检测慢性髓系白血病bcr‑abl1基因的表达量
CN108823306A (zh) *	2017-05-03	2018-11-16	杭州赫玛生物科技有限公司	检测白血病细胞的系统和方法
CN108676848B (zh) *	2018-05-31	2022-04-22	上海科医联创医学检验所有限公司	用于检测融合基因的混合基因、标准质粒、试剂盒及其制备方法
CN109554472A (zh) *	2018-12-18	2019-04-02	武汉迪安医学检验实验室有限公司	一种用于检测tel-aml1融合基因的试剂盒
CN111235148A (zh) *	2020-03-26	2020-06-05	迈杰转化医学研究(苏州)有限公司	一种dna探针池、包含其的淋巴瘤检测试剂盒及其制备方法和应用
CN111733238B (zh) *	2020-05-26	2021-08-03	广州血康陆道培生物技术有限公司	一种鉴别PML-RARα融合基因3种剪切体的引物组及其试剂盒和应用
CN112280866A (zh) *	2020-11-24	2021-01-29	福州艾迪康医学检验所有限公司	荧光定量pcr技术筛查急性早幼粒细胞白血病相关14种融合基因的方法、引物及探针
CN113637756A (zh) *	2021-08-18	2021-11-12	武汉良培医学检验实验室有限公司	一种用于多靶点单孔同时检测的探针组及其试剂盒
CN116970704B (zh) *	2023-08-22	2024-05-17	迈杰转化医学研究(苏州)有限公司	一种检测bcr-abl激酶区突变的引物探针组合及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6191255B1 (en) *	1995-07-14	2001-02-20	Fuji Yakuhin Kogyo Kabushiki Kaisha	Protein and monoclonal antibody specific thereto
AU2001239953A1 (en) *	2000-03-01	2001-09-12	University Of South Florida	Methods of modulating cell-adhesion mediated drug resistance
EP1272668B1 (de) *	2000-04-03	2007-02-14	Corixa Corporation	Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
AU2001278859A1 (en) *	2000-06-29	2002-01-14	University Of Florida	Ubiquitin ligase
US7363168B2 (en) *	2001-10-02	2008-04-22	Stratagene California	Adaptive baseline algorithm for quantitative PCR
US7198897B2 (en) *	2001-12-19	2007-04-03	Brandeis University	Late-PCR
DE10209071A1 (de) *	2002-02-28	2003-09-25	Roboscreen Ges Fuer Molekulare	Standardisierte Polynukleotidsysteme, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030170724A1 (en) *	2002-03-08	2003-09-11	Anderson David C.	Methods of identifying target polypeptides

2003
- 2003-03-07 EP EP03290572A patent/EP1454994A1/de not_active Withdrawn
2004
- 2004-03-08 WO PCT/EP2004/004008 patent/WO2004078020A2/en not_active Ceased
- 2004-03-08 JP JP2006505146A patent/JP4706863B2/ja not_active Expired - Lifetime
- 2004-03-08 AT AT04718310T patent/ATE518004T1/de not_active IP Right Cessation
- 2004-03-08 ES ES04718310T patent/ES2370339T3/es not_active Expired - Lifetime
- 2004-03-08 EP EP07007406A patent/EP1806415A3/de not_active Withdrawn
- 2004-03-08 US US10/548,188 patent/US20060240434A1/en not_active Abandoned
- 2004-03-08 AT AT07007462T patent/ATE445716T1/de not_active IP Right Cessation
- 2004-03-08 EP EP09175309A patent/EP2204457A3/de not_active Withdrawn
- 2004-03-08 EP EP07007462A patent/EP1806416B9/de not_active Expired - Lifetime
- 2004-03-08 ES ES07007462T patent/ES2337301T3/es not_active Expired - Lifetime
- 2004-03-08 DE DE602004023659T patent/DE602004023659D1/de not_active Expired - Lifetime
- 2004-03-08 EP EP04718310A patent/EP1601796B1/de not_active Expired - Lifetime
2011
- 2011-02-07 US US13/022,004 patent/US20110223595A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1806416B9 (de)	2010-03-10
US20110223595A1 (en)	2011-09-15
WO2004078020A3 (en)	2005-03-31
EP1806415A3 (de)	2007-07-18
US20060240434A1 (en)	2006-10-26
ES2337301T3 (es)	2010-04-22
DE602004023659D1 (de)	2009-11-26
EP1806416A3 (de)	2007-07-18
EP1806416B1 (de)	2009-10-14
EP1454994A1 (de)	2004-09-08
ATE518004T1 (de)	2011-08-15
EP1601796B1 (de)	2011-07-27
EP1806415A2 (de)	2007-07-11
JP2006519601A (ja)	2006-08-31
JP4706863B2 (ja)	2011-06-22
EP2204457A2 (de)	2010-07-07
EP2204457A3 (de)	2011-01-19
EP1806416A2 (de)	2007-07-11
EP1601796A2 (de)	2005-12-07
WO2004078020A2 (en)	2004-09-16
ATE445716T1 (de)	2009-10-15

Publication	Publication Date	Title
ES2370339T3 (es)	2011-12-14	Método normalizado y optimizado de reacción en cadena de la polimerasa de transcriptasa inversa cuantitativa en tiempo real para la detección de mrd en leucemia.
Vinci et al.	2011	Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers.
Weisser et al.	2005	Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy
Pyle et al.	2007	Depletion of mitochondrial DNA in leucocytes harbouring the 3243A→ G mtDNA mutation
KR20170010856A (ko)	2017-02-01	췌장암의 검출 키트 또는 디바이스 및 검출 방법
AL-Ammar	2020	Study on Correlation between IL-33 serum level, IL-33 Gene Single Nucleotide Polymorphism and Rheumatoid Arthritis Susceptibility.
Watzinger et al.	1998	Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays.
Padín-Iruegas et al.	2013	Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer
Gunadi et al.	2020	Aberrant expressions and variant screening of SEMA3D in Indonesian Hirschsprung patients
Cabiati et al.	2020	Aging and biomarkers: Transcriptional levels evaluation of Osteopontin/miRNA-181a axis in hepatic tissue of rats in different age ranges
CN105441565B (zh)	2018-09-18	作为骨肉瘤诊治靶标的miRNA
Duick	2012	Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer
Cheng et al.	2002	Microarray analysis of altered gene expression in the TM4 Sertoli-like cell line exposed to chromium (III) chloride
Xi et al.	2015	Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma
WO2004085675A1 (en)	2004-10-07	Method for identifying nucleic acid molecules associated with angiogenesis
ES2369415T3 (es)	2011-11-30	Procedimientos de diagnóstico que implican la determinación del número de copias de genes y de snp en el grupo de genes fc rii/fc riii y sondas para utilizar en dichos procedimientos para detectar la susceptibilidad a enfermedades autoinmunes y la eficacia de su tratamiento.
Taube et al.	2004	Real-time quantification of TEL–AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia: Comparison with antigen receptor-based MRD quantification methods
EP2557179A1 (de)	2013-02-13	Testverfahren zur bestimmung der anfälligkeit für eine immunsystem- oder gelenkerkrankung oder des stadiums einer solchen
HK1072076A (en)	2005-08-12	Standardized and optimized real-time quantitative reverse transcriptase polymerase chain reaction method for detection of mrd in leukemia
Youssef et al.	2019	Evaluation the time of death by different markers in liver and brain of rats
Rossi et al.	2006	Diagnosis and monitoring of PML-RARA-positive acute promyelocytic leukemia by qualitative RT-PCR
KR20210133199A (ko)	2021-11-05	연령에 따른 방광암의 예후 진단용 조성물 및 키트
Kirk	2020	Circadian rhythm evaluations to determine blood sample deposition time
Abdel-Aziz et al.	2024	LncRNAs AK058003 Overexpression in the Blood of a Group of Breast Cancer Egyptian females.
Sultana et al.	2008	rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh